Search Result
Results for "
I-As-1
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
7
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-163200
-
|
|
Cuproptosis
|
Neurological Disease
|
|
Cu(I) chelator 1 (Compound LH2) is a chelator which targets the Cu(I) redox state. Cu(I) chelator 1 prevents ROS production [1].
|
-
-
- HY-162407
-
|
|
Btk
|
Cancer
|
|
I-As-1 is a potent inhibitor of Bruton’s tyrosine kinase (BTK), with the IC50 of 2.35 nM. I-As-1 shows antiproliferative activities among Ramos cells and OCI-LY10 cells with IC50s of 0.52 μM and 0.11 μM, respectively [1].
|
-
-
- HY-146653
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
Glyoxalase I inhibitor 1 (compound 23) is a potent glyoxalase I (GLO1) inhibitor with an IC50 of 26 nM [1]. Glyoxalase I inhibitor 1 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-145859
-
-
-
- HY-157035
-
|
|
Proteasome
|
Others
|
|
Proteasome β2c/i-IN-1 (compound 37) is a subunit-selective human proteasome β2c and β2i inhibitor
.
|
-
-
- HY-145046
-
|
|
Ras
|
Cancer
|
|
SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1) [1].
|
-
-
- HY-U00159
-
-
-
- HY-B1411S1
-
-
-
- HY-18350A
-
|
LMP776 hydrochloride
|
Topoisomerase
|
Cancer
|
|
Indimitecan hydrochloride is a topoisomerase I (Top1) inhibitor with anticancer activities [1].
|
-
-
- HY-156297
-
|
|
Proteasome
|
Inflammation/Immunology
|
|
β5i-IN-1 is a potent and selective inhibitor of β5i with a IC50 of 8.463 nM. β5i-IN-1 releases TNF-α and IL-6 and influences the transcriptional activity of NF-κB. β5i-IN-1 can be used in study idiopathic pulmonary fibrosis [1].
|
-
-
- HY-168603
-
-
-
- HY-143766
-
|
|
Influenza Virus
|
Infection
|
|
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) [1].
|
-
-
- HY-N6905
-
-
-
- HY-18350
-
|
LMP776
|
Topoisomerase
|
Cancer
|
|
Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities [1].
|
-
-
- HY-N3983
-
|
|
Others
|
Others
|
|
Gynosaponin I (compound 1) is a natural product that can be found in Gynostemma pentaphyllum [1].
|
-
-
- HY-N12100
-
-
-
- HY-N10414
-
|
PrimulAsaponin 1; Primula acid I
|
Others
|
Others
|
|
Primulic acid I (Primulasaponin 1) is a plant-derived triterpenoid saponin with one sugar chain (monodesmoid) [1].
|
-
-
- HY-124211S
-
-
-
- HY-157281
-
-
-
- HY-15167A
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
Glyoxalase I inhibitor (free base) is a potent Glyoxalase I (GLO1) inhibitor, candidate for anticancer agents.
|
-
-
- HY-12777
-
-
-
- HY-N5038
-
|
|
Topoisomerase
|
Cancer
|
|
Mauritianin is a kaempferol glycoside isolated from the flowers and leaves of Acalypha indica. Mauritianin is a topoisomerase I inhibitor .
|
-
-
- HY-P99509
-
-
-
- HY-N1628
-
|
1-Hydroxybaccatin I
|
Others
|
Others
|
|
1β-Hydroxybaccatin I (1-Hydroxybaccatin I) can be extracted from Taxus wallichiana [1].
|
-
-
- HY-U00248A
-
|
MJ-III65 hydrochloride; NSC706744 hydrochloride
|
Topoisomerase
|
Cancer
|
|
LMP744 hydrochloride (MJ-III65 hydrochloride) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity [1].
|
-
-
- HY-U00248
-
|
MJ-III65; NSC706744
|
Topoisomerase
|
Cancer
|
|
LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity [1].
|
-
-
- HY-132893
-
|
|
TAM Receptor
|
Cancer
|
|
AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.
|
-
-
- HY-146657
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
4BAB (compound 29) is an irreversible glyoxalase I (GLO1) inhibitor. 4BAB has anticancer effects [1].
|
-
-
- HY-113681
-
-
-
- HY-N8614
-
|
|
Others
|
Others
|
|
Peucedanocoumarin I (compound 1) is a kind of dihydropyranocoumarin. Peucedanocoumarin I can be isolated from the root of f Peucedanum praeruptorum [1].
|
-
-
- HY-126752
-
-
-
- HY-126142
-
-
-
- HY-E70107
-
|
Cbh1
|
Others
|
Others
|
|
Cellobiohydrolase I (Cbh1) belongs to glycoside hydrolase family 7 (GH7) that catalyzes the processive hydrolysis of cellulose into cellobiose [1].
|
-
-
- HY-100841
-
|
3HPG
|
Others
|
Metabolic Disease
|
|
(Rac)-3-Hydroxyphenylglycine is an phosphoinositide hydrolysis agonist [1]. ACPD: I-aminocyclopcntane-1,3-dicarboxylic acid.
|
-
-
- HY-N7089
-
|
quinazolinedione
|
Bacterial
|
Infection
|
|
Benzoyleneurea possesses anti-bacterial activity. Benzoyleneurea scaffold can be used in the synthesis of novel protein geranylgeranyltransferase-I (PGGTase-I) inhibitors .
|
-
-
- HY-N6853
-
|
|
Others
|
Metabolic Disease
Cancer
|
|
Mogroside I E1 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities [1].
|
-
-
- HY-N6854
-
|
|
Others
|
Metabolic Disease
Cancer
|
|
Mogroside I A1 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities [1].
|
-
-
- HY-144466
-
-
-
- HY-P4044
-
|
|
HBV
|
Infection
|
|
HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules .
|
-
-
- HY-P10296
-
|
|
Endogenous Metabolite
|
Infection
|
|
p60 (217–225) is the subdominant epitope of Listeria monocytogenes, which combines with H-2K d MHC class I molecules .
|
-
-
- HY-19990
-
-
-
- HY-123052
-
-
-
- HY-W110910
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Eriochrome black T indicator (C.I. 14645), 1% solid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
-
- HY-139316
-
|
|
IRAK
PROTACs
|
Cancer
|
|
PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader extracted from patent US20190192668A1, compound I-171 .
|
-
-
- HY-P1104A
-
|
|
CXCR
HIV
|
Infection
|
|
FC131 TFA is a CXCR4 antagonist, inhibits [ 125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. Anti-HIV activity [1].
|
-
-
- HY-145107
-
-
-
- HY-113623
-
|
|
Others
|
Others
|
|
Pyrenophorol is a C9H12O3 compound isolated in low yield from culture filtrates of the phytopathogenic fungus Stemphylium radicinum, C.M.I. 105654 .
|
-
-
- HY-145840
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Pol I-IN-1 is a potent RNA polymerase I (Pol I) inhibitor with IC50 0.21 µM for the Pol I large catalytic subunit RPA194 [1].
|
-
-
- HY-117584
-
|
|
GHSR
|
Endocrinology
|
|
L-163255 free base is an orally active spiropiperidine GH secretagogue. L-163255 (free base) can also increase plasma IGF-I level .
|
-
-
- HY-113970A
-
|
WEB 1881 FU hydrochloride
|
mAChR
|
Neurological Disease
|
|
Nebracetam hydrochloride, a nootropic M1-muscarinic agonist, induces a rise of intracellular Ca 2+ concentration. Nebracetam hydrochloride exhibits an EC50 of 1.59 mM for elevating [Ca 2+]i .
|
-
- HY-N10414R
-
|
|
Others
|
Others
|
|
Primulic acid I (Standard) is the analytical standard of Primulic acid I. This product is intended for research and analytical applications. Primulic acid I (Primulasaponin 1) is a plant-derived triterpenoid saponin with one sugar chain (monodesmoid) [1].
|
-
- HY-146654
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
Glyoxalase I inhibitor 2 (compound 26) is a potent glyoxalase I (GLO1) inhibitor with an IC50 of 0.5 µM. Glyoxalase I inhibitor 2 has the potential for the research of depression and anxiety [1].
|
-
- HY-127167
-
|
|
Others
|
Inflammation/Immunology
|
|
3',4'-Dihydroxyflavone is a flavonoid. 3',4'-Dihydroxyflavone has antiallergic activity with an IC50 value of 30 μM. 3',4'-Dihydroxyflavone can be used for the research of type I allergy .
|
-
- HY-143545
-
|
|
RET
|
Cancer
|
|
RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer [1].
|
-
- HY-146655
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
Glyoxalase I inhibitor 3 (compound 22g) is a potent glyoxalase I (GLO1) inhibitor with an IC50 of 0.011 µM. Glyoxalase I inhibitor 3 has the potential for the research of depression and anxiety [1].
|
-
- HY-148974
-
|
|
Polo-like Kinase (PLK)
|
Cancer
|
|
PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4) .
|
-
- HY-118942
-
|
ARC 111
|
Topoisomerase
|
Cancer
|
|
Topovale (ARC 111) is a topoisomerase I inhbitor. Topovale is an antitumor agent, and shows low nM cytotoxicity against a panel of cancer cells. Topovale induces reversible topoisomerase I (TOP1) cleavage complexes in tumor cells [1].
|
-
- HY-19529
-
-
- HY-P1104
-
|
|
CXCR
HIV
|
Infection
|
|
FC131 is a potent CXCR4 antagonist. FC131 inhibits [ 125I]-SDF-1 binding to CXCR4 with an IC50 of 4.5 nM. FC131 has anti-HIV activity [1].
|
-
- HY-W008820S
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d6 is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
- HY-75161
-
|
|
TRP Channel
Endogenous Metabolite
|
Cancer
|
|
(-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca 2+-permeable nonselective cation channel, to increase [Ca 2+]i . Antitumor activity [1].
|
-
- HY-139315
-
|
|
PROTACs
IRAK
|
Cancer
|
|
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .
|
-
- HY-139317
-
|
|
PROTACs
IRAK
|
Cancer
|
|
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .
|
-
- HY-N12127
-
|
|
Others
|
Others
|
|
Gymnoside I (compound 1) is a glycosidoxybenzyl 2-isobutylmalic acid. Gymnoside I shows antiallergic activity in passive cutaneous allergic reaction (PCA) in mice. Gymnoside I can be used in research to treat asthma, neurasthenia and chronic hepatitis [1].
|
-
- HY-N11537
-
|
|
Others
|
Others
|
|
2-Methoxy-6-pentadecyl-1,4-benzoquinone (1c) is a pentadecyl derivative that can be isolated from seed oils of different iris plants such as I. pseudacorus, I. missouriensis and I. sibirica .
|
-
- HY-163684
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB) .
|
-
- HY-144641
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
|
-
- HY-144640
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
|
-
- HY-147985
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
hCA I-IN-1 (Compound 6q) is a human carbonic anhydrase I (hCA I) inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively [1].
|
-
- HY-N12200
-
|
|
Others
|
Cancer
|
|
Mollicellin I (compound 1) is a depsidone. The growth inhibitory activity of Mollicellin I on human breast cancer (Bre04), human lung (Lu04) and human neuroma (N04) cell lines is not significant, with GI50s >10 μg/mL [1].
|
-
- HY-15778A
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [ 125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM [1].
|
-
- HY-W008820S1
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d4 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
- HY-W008820S2
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d2 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
- HY-158412
-
|
|
Proteasome
Apoptosis
|
Cancer
|
|
BT317 is a blood-brain transmissible mitochondrial Lon peptidase I (LonP1) and CT-L proteasome inhibitor. BT317 can increase the production of reactive oxygen species (ROS) and induce apoptosis in astrocytoma cells. BT317 has antitumor activity [1].
|
-
- HY-P10486
-
|
|
Bacterial
|
Infection
|
|
AIP-II is a macrocyclic peptide signaling molecule used for quorum sensing, which can be produced be Staphylococcus aureus. AIP-II binds to AgrC-II receptor, regulates the virulence gene expression in Staphylococcus aureus. AIP-II is an antagonist for AgrC-I receptor .
|
-
- HY-143752
-
|
|
Influenza Virus
|
Infection
|
|
Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .
|
-
- HY-15544
-
|
|
CCR
|
Inflammation/Immunology
|
|
CCR1 antagonist 10 (example 1) is a potent and orally active CCR1 antagonist. CCR1 antagonist 10 inhibits 125I-MIP-1α binding to THP-1 cell membranes with an Ki value of 2.3 nM [1].
|
-
- HY-164151
-
|
|
ERK
|
Cancer
|
|
ERK-IN-8 (compound I-1) is an aniline pyrimidine derivative that acts as an ERK inhibitor. ERK-IN-8 has a strong inhibitory effect on ERK2 in vitro (IC50≤50 nM). ERK-IN-8 can be used in cancer research [1].
|
-
- HY-146094
-
|
|
Topoisomerase
|
Cancer
|
|
Antitumor agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, is an antitumor agent without toxicity towards normal cells. Antitumor agent-63 shows high stability and very weak direct topoisomerase I (Topo I) inhibition .
|
-
- HY-101037
-
|
N-Methylglycine; Sarcosin
|
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia [1] .
|
-
- HY-139909
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
|
-
- HY-139909A
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
|
-
- HY-120271
-
|
|
Ras
|
Cancer
|
|
GGTI-297 is a geranylgeranyl transferase I (GGTase-1) inhibitor with IC50 values of 56 nM and 203 nM for GGTase-1 and fanesyl transferase (FTase), respectively. GGTI-297 inhibits the processing of the geranylgeranylated protein Rap1A without affecting the farnesylated protein H-Ras [1] .
|
-
- HY-129421
-
|
|
PACAP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain [1].
|
-
- HY-118911
-
|
|
ATM/ATR
|
Cancer
|
|
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active ATM inhibitor (IC50: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .
|
-
- HY-P4109
-
|
NT21MP; V1 peptide
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) is an inhibitor of CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) [1].
|
-
- HY-133529
-
|
|
PACAP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
PA-8 is a potent, selective and orally active PACAP type I (PAC1) receptor antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC50 of 2 nM [1] .
|
-
- HY-145424
-
|
|
CDK
|
Others
|
|
CDK7-IN-10 is a CDK7 inhibitor with an IC50 of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell apoptosis [1].
|
-
- HY-101037S1
-
|
N-Methylglycine-d3; Sarcosin-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
|
-
- HY-143265
-
|
|
Topoisomerase
Apoptosis
Caspase
|
Cancer
|
|
Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect [1].
|
-
- HY-162551
-
|
|
Protoporphyrinogen IX oxidase
Others
|
Others
|
|
PPO-IN-13 (compound B16) is a potent inhibitor of protoporphyrinogen IX oxidase (PPO), with the Ki of 32.14 nM. PPO-IN-13 exhibits broad-spectrum and excellent 100% herbicidal effects to Echinochloa crusgalli, Digitaria sanguinalis, Setaria faberii, Abutilon juncea, Amaranthus retroflexus, and Portulaca oleracea at a concentration of 37.5 g a.i./ha .
|
-
- HY-P1016
-
|
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research 1 2.
|
-
- HY-101037S
-
|
N-Methylglycine-15N; Sarcosin-15N
|
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine- 15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
|
-
- HY-164429
-
|
|
Integrin
Elastase
|
Cancer
|
|
VIP236 is a small-molecule-drug conjugates (SMDCs) consisting of an αvβ3 integrin binder linked to an optimized Camptothecin (HY-16560) topoisomerase I (TOP1) inhibitor payload. VIP236 exerts anticancer activity by targeting αvβ3 integrins, and it can release payload upon cleavage by neutrophil elastase in the tumor microenvironment [1].
|
-
- HY-101037R
-
|
|
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia [1] .
|
-
- HY-P4109A
-
|
NT21MP TFA; V1 peptide TFA
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) [1].
|
-
- HY-P1839A
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-P1839
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-139015
-
|
5-Aza-T-dCyd; NTX-301
|
DNA Methyltransferase
|
Cancer
|
|
5-Aza-4'-thio-2'-deoxycytidine (5-Aza-T-dCyd) is an orally active DNA methyltransferase I (DNMT1) inhibitor. 5-Aza-4'-thio-2'-deoxycytidine, a sulfur-containing deoxy-cytidine analog, has the potential for DNA hypomethylating and has antitumor effects [1].
|
-
- HY-163570
-
|
|
Protoporphyrinogen IX oxidase
|
Others
|
|
PPO-IN-11 (Compound 10bh) is an inhibitor for protoporphyrinogen IX oxidase (PPO), that inhibits nicotiana tabacum PPO (NtPPO) with Ki of 0.0603 μM. PPO-IN-11 exhibits herbicidal activities against dicot weeds Leaf mustard, Chickweed, Chenopodium serotinum and monocot weeds Alopecurus aequalis, Poa annua, and Polypogon fugax with a dose of 150 g a.i./ha .
|
-
- HY-106994A
-
|
YM598
|
Endothelin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively [1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
|
-
- HY-106994
-
|
YM598 free bAse
|
Endothelin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively [1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
|
-
- HY-P1016B
-
|
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research [1] . .
|
-
- HY-10456
-
TAK-715
Maximum Cited Publications
12 Publications Verification
|
p38 MAPK
Casein Kinase
|
Inflammation/Immunology
|
|
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model [1] .
|
-
- HY-P1829
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-P1829A
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-158301
-
|
|
DNA Methyltransferase
|
Others
|
|
MY-1B is a covalent inhibitor of the RNA Methyltransferase NSUN2 (IC50: 1.3 μM). MY-1B stereoselectively ligands active-site cysteine residues (C271) of NSUN2. MY-1B can stereoselectively and covalently bind to PSME1, disrupting the proteasome regulatory complex and downregulating the presentation of specific MHC-I subtypes .
|
-
- HY-130538
-
|
|
HDAC
|
Cancer
|
|
1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC50 of 14 μM. 1-Naphthohydroxamic acid is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC50 >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity [1] [2].1-Naphthohydroxamic acid can induce tubulin acetylation .
|
-
- HY-119939
-
|
|
HDAC
|
Cancer
|
|
CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform [1].
|
-
- HY-P99171
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) [1] .
|
-
- HY-135283
-
|
A-216546
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
ABT-546 (A-216546) is a potent, highly selective and active endothelin ETA receptor antagonist with a Ki of 0.46 nM for [ 125I]endothelin-1 binding to cloned human endothelin ETA. ABT-546 is >25,000-fold more selective for the ETA receptor than for the ETB receptor. ABT-546 blocks endothelin-1-induced arachidonic acid release and phosphatidylinositol hydrolysis with IC50 of 0.59 nM and 3 nM, respectively [1].
|
-
- HY-W103463
-
|
1-Phenylpyrrolidin-2-one
|
GABA Receptor
|
Neurological Disease
|
|
1-Phenyl-2-pyrrolidinone (1-Phenylpyrrolidin-2-one) is a phenyl analogue of GABA with sedative effect, decreasing the exploratory behavior of rats at 50-100 mg/kg (i.v.). 1-Phenyl-2-pyrrolidinone also has been proved to inhibit emotional reactions in dogs and cats. 1-Phenyl-2-pyrrolidinone induces decreases in the pressor reaction to emotional stress without accompanied by normalization of the function of baroreceptor reflexes [1] .
|
-
- HY-101823A
-
|
Abbott 81282
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
A-81282 (Abbott 81282) is an antagonist of angiotensin II's AT1 receptor, with a pA2 value of 9.64 at the AT1 receptor in rabbit aorta. A-81282 also demonstrates significant inhibitory action on the binding of [125i]_Sar1_lle8_Angiotensin_ll to rat liver membranes, with a pKI value of 8.505. A-81282 has antihypertensive activity and can effectively lower blood pressure in renal artery-ligated rats [1].
|
-
- HY-125990
-
|
|
Sodium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5 .
|
-
- HY-137460
-
|
K0706
|
Bcr-Abl
|
Cancer
|
|
Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research [1] . Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-163117
-
|
|
COX
Carbonic Anhydrase
|
Neurological Disease
Inflammation/Immunology
|
|
Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonic anhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonic anhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII) [1].
|
-
- HY-P1110
-
AF12198
1 Publications Verification
|
Interleukin Related
|
Inflammation/Immunology
|
|
AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo [1].
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W110910
-
|
|
Indicators
|
|
Eriochrome black T indicator (C.I. 14645), 1% solid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1104A
-
|
|
CXCR
HIV
|
Infection
|
|
FC131 TFA is a CXCR4 antagonist, inhibits [ 125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. Anti-HIV activity [1].
|
-
- HY-P4109A
-
|
NT21MP TFA; V1 peptide TFA
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) [1].
|
-
- HY-P4812
-
|
|
Peptides
|
Metabolic Disease
|
|
Prepro-von Willebrand factor (641-650) (bovine) is a fragment of Prepro-von Willebrand factor, which binds to type I collagen .
|
-
- HY-P4044
-
|
|
HBV
|
Infection
|
|
HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules .
|
-
- HY-P10296
-
|
|
Endogenous Metabolite
|
Infection
|
|
p60 (217–225) is the subdominant epitope of Listeria monocytogenes, which combines with H-2K d MHC class I molecules .
|
-
- HY-P1104
-
|
|
CXCR
HIV
|
Infection
|
|
FC131 is a potent CXCR4 antagonist. FC131 inhibits [ 125I]-SDF-1 binding to CXCR4 with an IC50 of 4.5 nM. FC131 has anti-HIV activity [1].
|
-
- HY-P10486
-
|
|
Bacterial
|
Infection
|
|
AIP-II is a macrocyclic peptide signaling molecule used for quorum sensing, which can be produced be Staphylococcus aureus. AIP-II binds to AgrC-II receptor, regulates the virulence gene expression in Staphylococcus aureus. AIP-II is an antagonist for AgrC-I receptor .
|
-
- HY-P5526
-
|
|
Peptides
|
Others
|
|
CCK1-specific peptide substrate is a biological active peptide. (This peptide sequence is based on rabbit muscle glycogen synthase with Ser7 phosphorylated. It is a peptide substrate for Casein Kinase I (CK1). CK1 phosphorylates Ser10. Ser7 is phosphorylated by PKA in vivo.)
|
-
- HY-P4109
-
|
NT21MP; V1 peptide
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) is an inhibitor of CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) [1].
|
-
- HY-P1016
-
|
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research 1 2.
|
-
- HY-P1839A
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-P1839
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-P1016B
-
|
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research [1] . .
|
-
- HY-P1829
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-P1829A
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy [1] .
|
-
- HY-P1110
-
AF12198
1 Publications Verification
|
Interleukin Related
|
Inflammation/Immunology
|
|
AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo [1].
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99509
-
-
- HY-P99171
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) [1] .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W008820S
-
1 Publications Verification
|
|
Glutaric acid-d6 is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
-
- HY-W008820S1
-
|
|
|
Glutaric acid-d4 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
-
- HY-101037S1
-
|
|
|
Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
|
-
-
- HY-101037S
-
|
|
|
Sarcosine- 15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
|
-
-
- HY-B1411S1
-
|
|
|
i-Inositol-d is the deuterium labeled i-Inositol[1].
|
-
-
- HY-124211S
-
|
|
|
Dibenzo(a,i)pyrene-d14 is the deuterium labeled Dibenzo(a,i)pyrene[1].
|
-
-
- HY-W008820S2
-
|
|
|
Glutaric acid-d2 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-146653
-
|
|
|
Alkynes
|
|
Glyoxalase I inhibitor 1 (compound 23) is a potent glyoxalase I (GLO1) inhibitor with an IC50 of 26 nM [1]. Glyoxalase I inhibitor 1 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-75161
-
|
|
|
Flavoring Agents
|
|
(-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca 2+-permeable nonselective cation channel, to increase [Ca 2+]i . Antitumor activity [1].
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
